TG Therapeutics, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 6.69M | 2.79M | 233.66M | 329.00M | 616.29M | 87.3% | |
| Cost of Revenue | (790.00K) | (265.00K) | (14.13M) | (38.49M) | (100.71M) | 161.7% | |
Gross Profit | 5.90M | 2.52M | 219.53M | 290.52M | 515.57M | 77.5% | |
| Operating Expenses | |||||||
| Research & Development | (222.58M) | (125.35M) | (76.19M) | (94.29M) | (160.22M) | 69.9% | |
| Selling, General & Administrative | (128.09M) | (95.48M) | (122.71M) | (154.30M) | (232.03M) | 50.4% | |
| General & Administrative | (128.09M) | (95.48M) | (122.71M) | (154.30M) | (232.03M) | 50.4% | |
| Depreciation & Amortization | (494.00K) | (515.00K) | (423.00K) | (280.00K) | (244.00K) | -12.9% | |
Operating Income (EBIT) | -344.77M | -218.32M | 20.63M | 41.93M | 123.32M | 194.1% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (5.64M) | (10.19M) | (12.62M) | (24.03M) | (26.73M) | 11.2% | |
| Other Income/Expenses (Net) | -3.33M | -5.50M | -7.57M | -16.34M | -15.93M | -2.5% | |
Income Before Tax | -348.10M | -223.81M | 13.06M | 25.59M | 107.39M | 319.6% | |
| Income Tax Expense | — | — | (390.00K) | (2.21M) | (339.79M) | -15468.1% | |
Net Income | -348.10M | -223.81M | 12.67M | 23.38M | 447.18M | 1812.4% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-3 | $-1 | $0 | $0 | $3 | 1837.5% | |
| Weighted Avg Shares Outstanding | 132.22M | 135.41M | 141.96M | 145.32M | 144.32M | -0.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 132.22M | 135.41M | 148.51M | 160.34M | 161.41M | 0.7% | |
EBITDA | -341.97M | -213.11M | 26.10M | 49.90M | 134.36M | 169.2% |
Explore TGTX
TGTX in the Healthcare
Mid Cap